Cardenolide B-1 is primarily investigated for its potential in cancer therapy due to its ability to inhibit the sodium-potassium ATPase pump, which plays a critical role in maintaining cellular ion balance. This inhibition triggers signaling pathways that can lead to apoptosis in cancer cells, making it a candidate for anticancer drug development. It has shown particular interest in targeting resistant tumor cells, where conventional therapies fail. Research also explores its use in combination with other chemotherapeutic agents to enhance efficacy and reduce drug resistance. Additionally, due to its structural similarity to cardiac glycosides, studies are evaluating its cardiovascular effects, though therapeutic applications remain focused on oncology.